moon
Lv10
32440 积分
2023-04-20 加入
-
Data from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
11天前
已完结
-
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
28天前
已完结
-
The co-expression of antigen targets as a rationale for ADCs combination in urothelial cancer
30天前
已完结
-
The biology and rationale of targeting nectin-4 in urothelial carcinoma
30天前
已完结
-
Membranous expression of target protein is required for ADC response in urothelial cancer
30天前
已完结
-
Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus
2个月前
已完结
-
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
2个月前
已完结
-
Elranatamab: a new promising BispAb in multiple myeloma treatment
2个月前
已完结
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
2个月前
已完结
-
Tebentafusp: First Approval
3个月前
已完结